Moreover, the empagliflozin attenuates atherogenesis and endothelial dysfunction in diabetic ApoE−/− mice by modulating the expression of MCP-1, CD68, and subunits of NADPH oxidase in macrophages [213]. This evidence concerns the gene CCL2 and endothelial dysfunction.